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Background: Despite penile carcinoma (PeCa) being a relatively rare neoplasm, it remains an important public
health issue for poor and developing countries. Contrary to most tumors, limited data are available for markers that
are capable of assisting in diagnosis, prognosis, and treatment of PeCa. We aimed to identify molecular markers for
PeCa by evaluating their epigenomic and transcriptome profiles and comparing them with surrounding non-malignant
tissue (SNT) and normal glans (NG).
Results: Genome-wide methylation analysis revealed 171 hypermethylated probes in PeCa. Transcriptome profiling
presented 2,883 underexpressed and 1,378 overexpressed genes. Integrative analysis revealed a panel of 54 genes with
an inverse correlation between methylation and gene expression levels. Distinct methylome and transcriptome patterns
were found for human papillomavirus (HPV)-positive (38.6%) and negative tumors. Interestingly, grade 3 tumors
showed a distinct methylation profile when compared to grade 1. In addition, univariate analysis revealed that low
BDNF methylation was associated with lymph node metastasis and shorter disease-free survival. CpG hypermethylation
and gene underexpression were confirmed for a panel of genes, including TWIST1, RSOP2, SOX3, SOX17, PROM1, OTX2,
HOXA3, and MEIS1.
Conclusions: A unique methylome signature was found for PeCa compared to SNT, with aberrant DNA methylation
appearing to modulate the expression of specific genes. This study describes new pathways with the potential
to regulate penile carcinogenesis, including stem cell regulatory pathways and markers associated to a worse
prognosis. These findings may be instrumental in the discovery and application of new genetic and epigenetic
biomarkers in PeCa.
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Penile carcinoma (PeCa) is a rare neoplasm in developed
countries, with an incidence of 0.5 to 1.1 per 100,000 in
Europe [1]. However, it represents an important public
health problem for poor and developing countries, such
as in Brazil, where its incidence varies from 2.9 to 6.8* Correspondence: rogatto@fmb.unesp.br
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gions of South America, it is responsible for up to 10%
of malignancies that affect men [3]. The etiology and
various aspects of PeCa pathophysiology are still poorly
understood, with poor penile hygiene and the presence
of phimosis being the most strongly associated risk
factors [4]. The incidence of the disease differs more
than 40-fold in countries where neonatal circumcision
and appropriate hygiene are common practice [5].
Other risk factors, such as the number of sexual partners,
a history of genital warts and/or other sexually transmitted. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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smoking, and zoophilia, have also been described [6,7].
Human papillomavirus (HPV) infection is considered to
be a risk factor for a subset of PeCa, although its role in
penile carcinogenesis has not been clarified [8-10].
PeCa has an unpredictable outcome, and its current
treatment requires partial or total penile amputation.
There are few molecular studies on PeCa, with the ma-
jority of them having focused on protein expression
levels or genetic/epigenetic alterations of specific genes
[11,12]. DNA methylation, histone modification, and
regulation by non-coding RNA regulate gene expression
by controlling chromatin accessibility and transcription
[13]. Alterations of epigenetic markers have been associ-
ated with the development and progression of various
tumors [14]. In PeCa, one of the most studied epigenetic
alterations is the hypermethylation of the CDKN2A gene
promoter, which has been found in 15% to 42% of samples
[15]. To date, only one study has analyzed the transcrip-
tome [16], while another has evaluated the epigenetic
profile in PeCa [17]. Kroon et al. [16] evaluated 56 PeCa
samples using oligoarray analysis and found a 44-probe
classifier that predicted lymph node metastasis. How-
ever, validation analysis in an independent set of
samples failed to confirm it as useful to predict nodal
metastases in PeCa. More recently, Feber et al. [17] used
high-density genome-wide methylation array to evaluate
the methylation profile of 38 PeCa samples and identi-
fied epi-signatures related to HPV infection and lymph
node metastasis. However, none of these studies have
evaluated the impact of DNA methylation on gene ex-
pression using large-scale analysis. In the present study,
integrated transcriptome and methylome data were
used to identify novel epigenetically regulated tran-
scripts with a potential clinical application.
Results
Genome-wide methylation, transcriptome, and integrative
analysis
The methylation profile of 25 PeCa, 10 surrounding
non-malignant tissues (SNT), and 4 normal glans (NG)
samples was evaluated using methyl-CpG immunopre-
cipitation microarray (MCIp-chip) (Additional file 1:
Figure S1). Reproducibility of the MCIp-chip experi-
ments was controlled by using technical replicates of
one randomly selected case (Pearson correlation, r2 =
0.93 P value ≤ 2.2e−16). Microarray analysis revealed
similar methylome profiles for a pool of four NG and
SNT samples, confirming that SNT could be used as a
control in the PeCa analysis (data not shown). Using 10
paired PeCa and SNT samples, 171 hypermethylated
probes were identified (false discovery rate (FDR) ≤ 0.05;
P value ≤ 0.001) (Figure 1A, B), which represented 106
annotated genes (Additional file 2: Table S1). Ninety-twopercent of the differentially methylated probes were
located within promoter regions. In addition, pyrose-
quencing revealed a global hypomethylation in PeCa
samples when compared to NG and SNT, with an aver-
age methyl-cytosine loss of 15% in ALR1Sat and AluYB8
sequences (Additional file 1: Figure S2).
Transcriptome analysis was performed on 33 PeCa
samples, revealing 3,637 underexpressed (2,883 annotated
genes) and 1,730 overexpressed probes (1,378 genes).
Interestingly, six members of the matrix metalloproteinase
gene family (MMPs) were detected among the 30 genes
with a higher fold change in PeCa (Additional file 2:
Table S2).
Integrative analysis was performed using both methy-
lome and transcriptome data from 25 samples. This
analysis revealed that 54 of the 106 hypermethylated
genes (51%), including RSPO2 and SOX17, also pre-
sented reduced levels of expression (Figure 2A), which
was subsequently validated by pyrosequencing and RT-
qPCR (Additional file 1: Figures S2 and S3).
Twenty probes (representing 20 genes) were selected
for validation by pyrosequencing analysis. Paired (18 PeCa
and SNT) and unpaired samples (44 PeCa, 30 SNT, and
11 NG) were included. Eighteen of 20 probes confirmed
the MCIp-chip findings in the paired analysis, while all of
them were validated in the unpaired samples (Additional
file 1: Figure S2). Twelve of the 20 genes that were eval-
uated by pyrosequencing also underwent RT-qPCR
analysis. Significant underexpression was observed for 8
genes (TWIST1, RSPO2, SOX3, SOX17, PROM1, OTX2,
HOXA3, and MEIS1) (Additional file 1: Figure S3). Table 1
summarizes the results obtained from the microarray,
pyrosequencing, and RT-qPCR analyses. Correlation
analysis for methylation levels and gene expression de-
tected by pyrosequencing and RT-qPCR showed a
significant inverse correlation for the SOX17, RSPO2,
PROM1, and HOXA3 genes (Figure 2B).
Transcriptome and methylome profiles are influenced by
HPV infection
Seventeen of the 44 PeCa (38.6%) evaluated in this study
were HPV-positive, the vast majority for subtype 16
(88.2%). Unsupervised analysis revealed that HPV status
influenced both gene expression levels and methylation
patterns (Figure 1C, D). Three thousand forty-nine
differentially methylated probes and 1,119 differentially
expressed genes were identified in the HPV-positive
cases when compared to HPV-negative cases (fold
change > 1.5). Hierarchical clustering analysis of the
transcriptome data revealed a cluster that comprised of
solely HPV-positive PeCa (9/9 cases). The remaining HPV-
positive cases clustered with HPV-negative samples (2/24).
These clusters were noted to be significantly different when
submitted to the chi-squared test (P value = 0.000005)
Figure 1 (See legend on next page.)
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Figure 1 Supervised and unsupervised analysis of gene expression and methylation profiles. (A) Heat map showing 171 significantly
hypermethylated probes in the paired analysis of 10 PeCa and SNT samples (P value ≤0.001 and FDR ≤0.05). (B) Volcano plot of the methylated
regions: left-sided deviation indicates that all hypermethylated probes were tumor related. (C) Unsupervised analysis showing dendogram and
heat map of altered transcripts from the gene expression analysis in PeCa. (D) Unsupervised analysis showing dendogram and heat map of al-
tered probes from the methylation analysis in 25 PeCa samples. Rectangles show clinical characteristics of patients with PeCa. Numbers below
rectangles represent samples.
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data also revealed an HPV-positive tumor-enriched
cluster (7/11 cases, 88%). Only one HPV-positive sam-
ple was observed to be grouped with the HPV-negative
cases (1/14, 24%, P = 0.034) (Figure 1D). Integrative
analysis performed on 25 cases (7 HPV-positive and 18
HPV-negative) revealed the presence of 65 inversely
correlated genes (hypermethylated and underexpressed)
in HPV-positive cases, including CD70, HN1, FZD5,
FSCN1, and PRR16 (correlation coefficient < −0.60 and
P value < 0.05). Similarly, 60 genes were detected in the
HPV-negative cases (Additional file 2: Table S3).
Comparison between global methylation and expression
profile and clinicopathological features
Unsupervised hierarchical clustering analysis of gene ex-
pression revealed a group of HPV-negative cases that
were related to a poor prognosis, whether due to recur-
rence, lymph node metastasis, high histology grade, or
death (Figure 1C). A distinct methylome profile was de-
tected according to histological grading. Grade 2 and 3
tumors presented similar methylation profiles, which
were different from grade 1 (Additional file 1: Figure
S4A). The methylation profiles were particularly differ-
ent when poorly differentiated (grade 3) were compared
to well-differentiated tumors (grade 1) (Additional file 1:
Figure S4B). This comparison revealed the presence of
122 differentially methylated probes in grade 3 tumors,
including hypermethylated probes representing the
BCL3, OTOP1, and PAX2 genes. This methylome signa-
ture was considered unique to tumor grade, with none
of the probes being altered in other comparisons.
Enrichment and upstream regulator analyses were per-
formed for the 122 differentially methylated probes
found for the grade 3 tumors. Extracellular matrix re-
ceptor interaction, cell migration, and developmental
biology were the principal pathways identified (corrected
P value <0.05, Additional file 2: Table S4).
The 20 genes selected for validation by pyrosequenc-
ing and the 12 genes selected for RT-qPCR were evalu-
ated with regard to their clinical features. Univariate
analysis revealed that low NKX2-3 and BDNF methyla-
tion levels were associated to a shorter disease-free sur-
vival (Additional file 1: Figure S4C and D, respectively).
Low BDNF methylation levels were also associated with
lymph node metastases (P = 0.035). Low LIN28A (P =0.023) and CDX2 (P = 0.041) methylation levels were as-
sociated with advanced clinical stage (III and IV). In
addition, FOXA1 overexpression was associated with
perineural invasion (P = 0.033), while OTX2 overexpres-
sion was associated with angiolymphatic invasion (P =
0.040) (Additional file 2: Table S5). However, after
multiple-comparison correction, these findings were not
validated.
In silico molecular enrichment analysis
Enrichment analysis, alongside the use of the Ingenuity
Pathway Analysis (IPA) software, was used to identify
gene function annotation and canonical pathways. These
analyses were performed for the genes that presenting
altered expression or methylation patterns, with the ob-
jective of gaining an insight into the onco-pathogenic
pathways of PeCa. KOBAS and Gene Set Enrichment
Analysis (GSEA) software were used to confirm the re-
sults (Additional file 2: Table S6). Hypermethylated
genes were related to embryonic, cellular, and organism
developmental functions. The most significant functions
identified for the genes with altered expression were cell
and embryonic development, cell movement, migration,
growth and proliferation, cell cycle, and angiogenesis.
Pathway analysis, which was performed using IPA,
KOBAS, and GSEA software, identified altered genes re-
lated to the molecular mechanisms of carcinoma, tran-
scriptional regulatory networks in embryonic stem cells,
Wnt/β-catenin signaling, and cell cycle. In addition, up-
stream regulator analysis of the differentially expressed
genes was performed, revealing 40 altered genes, which
were considered as involved in the activation/inactiva-
tion of 126 genes in PeCa (Additional file 2: Table S7).
Among these genes, PIK3CD, FGF1, ILIA, ILIB, and
TNK are already established therapeutic targets with the
potential to be used in clinical practice.
Discussion
Genome-wide studies revealed methylome signatures
that can stratify cancer subtype [18], predict cancer out-
come [19], and identify “driver” epigenetic events, which
promote cancer cell survival [20]. In this study, genome-
wide methylation analysis of penile cancer revealed 171
hypermethylated probes, 20 of which were validated by
pyrosequencing. Hypomethylated probes were not identi-
fied, which may be partially explained by the experimental
Figure 2 (See legend on next page.)
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Figure 2 Circular plot and correlation graphics. (A) Circular representation of the genes with inverse correlation between gene expression and
methylation. Fifty-four hypermethylated/underexpressed genes are shown. The tracks on the outside represent (1) genes, (2) chromosomes, (3)
gene expression, and (4) methylation. (B) Graphic representation of gene expression, methylation, and Spearman correlation for the SOX17, RSPO2,
CD133, and HOXA3 genes. First column - relative gene expression levels by quantitative RT-PCR; second column - methylation levels by
pyrosequencing; third column - Spearman correlation. NG: normal glans; SNT: surrounding non-malignant tissue; PeCa: penile carcinoma;
NS: not significant; *: P value ≤0.05.
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DNA. In addition, the microarray platform mainly focused
on promoter regions and CpG islands and the filter
used in the identification of the differentially methylated
probes was very stringent. Furthermore, global hypome-
thylation of the PeCa genome was observed via the ana-
lysis of methylation levels of the AluYB8 and AIR1Sat
repetitive sequences. This is consistent with the notion
that global loss of methyl-cytosine is a universal cancer-
associated phenomenon related to increased genomic
instability [21].
Transcriptome analysis identified 4,261 differentially
expressed genes. Six MMP genes (MMP1, MMP7, MMP9,
MMP10, MMP12, and MMP13) were detected among
the top 30 overexpressed transcripts (Additional file 2:Table 1 Differentially methylated genes as revealed by
genome-wide methylation analysis, which were selected
for validation by pyrosequencing and RT-qPCR
Genes MCIp-chip Pyrosequencing Expression (RT-qPCR)
RSPO2 • • Underexpressed
TWIST1 • • Underexpressed
SOX3* • • Underexpressed
SOX17 • • Underexpressed
PROM1/CD133 • • Underexpressed
HOXA3* • • Underexpressed
MEIS1 • • Underexpressed
OTX2 • • Underexpressed
SOX14 • • N.S.
ONECUT1 • • N.S.
PAX7 • • N.S.
FOXA1 • • N.S.
LHX5 • • -
BDNF • • -
NKX2.2 • • -
NKX2.3 • • -
CDX2 • • -
ONECUT2 • • -
LIN28A • • -
WIT1 • • -
•: methylated probe, P value ≤0.05; N.S.: not significant; − not performed; *For
these genes, P value ≤0.05 was obtained from the Mann–Whitney test. For all
other genes, significance was obtained using the Kruskal-Wallis test.Table S2). Accordingly, one of the functions identified
by IPA, KOBAS, and GSEA was related to extracellular
matrix dysregulation (Additional file 2: Table S6). In
addition, the MMP-9 protein has been shown to be an
independent risk factor for cancer recurrence in PeCa
[22]. To explore the interactions between the transcripts,
as well as to identify putative transcriptional regulators
with the potential to be therapeutic targets, an upstream
regulator analysis was performed. The prediction of this
analysis was supported by the expected direction expres-
sion of the downstream factors in the input gene list. The
differentially expressed transcripts predicted the inhibition
of 17 genes and activation of 23 genes, which were shown
to be under- and overexpressed, respectively in PeCa when
compared to NG. The analysis revealed the PIK3CD,
FGF1, IL1A, IL1B, and TNF genes as having the potential
of being therapeutic targets (Additional file 2: Table S7).
Integrative analysis using methylome and transcrip-
tome data revealed underexpression of 51% of the
hypermethylated genes (54 of 106). In an independent
group of samples, an inverse correlation was also ob-
served between the methylation and transcript levels.
The 20 probes selected for validation using pyrose-
quencing confirmed the results obtained in the micro-
array analysis. In addition, the expression levels for 8 of
the 12 genes evaluated by RT-qPCR were inversely
correlated with methylation status, suggesting that methy-
lation is associated with dysregulation of these genes.
Although HPV infection is one of the risk factors asso-
ciated to PeCa, few studies have evaluated its impact on
DNA methylation changes. A recent study revealed that
HPV-16 infection influenced the epigenetic profile of
PeCa [17]. In the present study, 38.6% of the cases were
HPV-positive. When comparing HPV-positive and nega-
tive PeCa, integrative analysis of the transcriptome and
methylome revealed the presence of 65 hypermethylated
and underexpressed genes in the HPV-positive tumors.
In addition, unsupervised hierarchical clustering analysis
revealed a specific group of genes in HPV-positive PeCa
with altered methylation and expression levels, which is
consistent with the hypothesis that HPV dysregulates
specific signaling pathways that participate in penile
carcinogenesis [8-10].
One of the interesting findings in this study was that
aside HPV infection, other pathways, such as cellular
and embryonic development and stem cell regulation
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genes involved in cellular differentiation during embryonic
development (NKX2-2, NKX2-3, ONECUT1, ONECUT2,
TWIST1, PROM1, MEIS1, HOXA3, CDX2, OTX2, FOXA1,
and LHX5) [23,24] was also identified. Accordingly,
transcript levels for seven of these genes were evaluated,
with five of them (MEIS1, HOXA3, OTX2, TWIST1, and
PROM1) being underexpressed in the tumor samples.
Aberrant methylation in several members of the SOX
family genes, including SOX1, SOX3, SOX9, SOX14,
SOX17, and SOX20T, was also observed. Recent evi-
dence suggests that many SOX family genes physically
interact with the β-catenin/Wnt signaling pathway,
which regulates the transcription of target genes in-
volved in embryonic patterning, development, and stem
cell maintenance [25]. Furthermore, enrichment ana-
lysis revealed the transcriptional regulatory network in
embryonic stem cells as the major canonical pathway
involved in PeCa (P value = 0.00097).
Interestingly, the methylation profile of PeCa was
capable of differentiating the samples according to histo-
logical grade. One hundred and twenty-two probes were
differentially methylated in grade 3 tumors (Additional
file 1: Figure S4), with the principal pathways involved in
this group being extra cellular matrix receptor interaction
and cell migration. Dysregulation of these pathways con-
tribute to neoplastic progression and cell migration [26],
supporting the results of the present study.
The strongest prognostic factor for PeCa is lymph
node metastasis [4]. However, no useful clinical molecu-
lar markers to predict PeCa outcome are available.
Prognostic markers for inguinal metastases could aid
in the stratification of patients at higher risk. Thus,
unnecessary prophylactic inguinal lymphadenectomy,
which is associated with high morbidity, could be
avoided. Univariate analysis revealed that low BDNF
methylation was associated with lymph node metastasis
and a shorter disease-free survival. Although further
studies are required in order to validate this finding, we
propose BDNF as a potential prognostic molecular
marker for PeCa. Univariate analysis also identified
other putative prognostic markers that could be used
clinically (Additional file 2: Table S5). Multivariate ana-
lysis did not confirm these findings, probably due to the
small sample size and number of adverse events (death/
recurrence).
Conclusions
This study identified novel epigenetically regulated genes
in penile carcinogenesis. Several genes were validated
and associated with transcript expression levels and
clinical parameters. The dysregulated genes detected are
known to be associated with essential cellular processes,
which suggest that they play an important role in thedevelopment and progression of this disease. Our data
also suggests an association between the involvement of
the stem cell regulatory pathway to differential prognosis
in PeCa. This study may prove instrumental in the dis-




Forty-four usual-type penile squamous cell carcinomas
(SCC), surrounding non-malignant tissue (SNT; N = 30),
and 13 normal glans (NG), the latter obtained from nec-
ropsy, from the AC Camargo Cancer Center, São Paulo,
SP, Brazil, and Barretos Cancer Hospital, Barretos, SP,
Brazil, were used. The SNT samples were obtained from
as far away as possible from the tumor margin. They were
composed mainly of squamous cells, considered histologi-
cally normal, and thus used as a reference in our experi-
ments. Patient progress was monitored prospectively, with
a mean follow-up of 20 months (1 to 67 months). Eighty-
four percent of the patients were submitted to partial pen-
ectomy, with none having been treated prior to sample
collection. Patients and/or family members were coun-
seled regarding the procedure and subsequently provided
written informed consent. The Human Research Ethics
Committees of the aforementioned institutions approved
the study. Clinical and histopathological data are summa-
rized in Additional file 2: Table S8.
DNA from frozen penile tissue was isolated using the
DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA),
and RNA was extracted using RNeasy ™ (Qiagen). RNA in-
tegrity was confirmed using the Agilent 2100 Bioanalyzer
RNA 6000 LabChip kit (Agilent Technologies, Santa
Clara, CA, USA). HPV status was established for all PeCa
via Linear Array HPV Test Genotyping (Roche Molecular
Diagnostics, Branchburg, NJ, USA). Furthermore, primers
binding to the L1 region of the HPV virus (primers pair
GP5+/GP6+) were also used [27].
Twenty-five of the 44 PeCa samples and 10 SNT were
evaluated using methylation microarray. Validation by
quantitative bisulfite pyrosequencing was performed on
samples used in the microarray (technical validation; 25
PeCa and 10 SNT), as well as an independent set of
samples (biological validation; 19 PeCa, 20 SNT and 11
glans samples). Thirty-one PeCa RNA samples were
used for gene expression profiling, while 39 PeCa were
used for RT-qPCR analysis, of which, 8 PeCa, 13 SNT,
and 8 glans were independent of global gene expression
microarray. Detailed information of the sample selection
is described in Additional file 1: Figure S1.
Genome-wide methylation microarray
Enrichment of methylated sequences was performed
for a subset of 25 PeCa and 10 SNT. The Methyl-CpG
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protocol [28] was used to investigate methylated CpG-rich
sequences (MethylMiner Methylated DNA Enrichment,
Invitrogen Life Technologies, Carlsbad, CA, USA).
Genome-wide methylation assays were performed using
the Agilent 244 K Human DNA Methylation Microarray
(Agilent Technologies) as per the manufacturer’s recom-
mendations. Workbench Standard (Ed. 5.0.14, Agilent
Technologies) and BRB ArrayTools software (v. 4.2.1) [29]
were used for microarray data normalization (Lowess) and
statistical analyses. Genes whose methylation levels dif-
fered by at least 1.5 fold from the median in at least 20%
of the arrays were retained. Using the random-variance
t-test [30], differentially methylated genes were identified
among the PeCa and SNT samples. The random-variance
t-test is an improvement over the standard separate t-test
and permits the sharing of information between genes
concerning within-class variation without assuming that
all genes have the same variance. Genes were considered
statistically significant if their P value was less than 0.001.
A stringent significance threshold was used to limit the
number of false positive findings (FDR ≤0.05).
Transcriptome analysis
Transcriptome analysis of 33 PeCa (labeled with Cy3)
and a pool of five NG obtained from necropsies (labeled
with Cy5) were evaluated using the Whole Human
Genome 4 × 44K microarray platform (Agilent Tech-
nologies) according to the manufacturer’s recommenda-
tions. Images were acquired using a DNA microarray
scanner (Agilent Technologies) and processed by the
Feature Extraction Software (v. 10.1.1.1). Background-
corrected mean signal intensity from each dye channel
was used. Microarray data were normalized (Lowess)
using the Agilent Feature Extraction Software (v.10.1.1.1).
Additionally, a filter was applied to remove values with
low reproducibility. Genes with a mean log2 signal ratio
(Cy3/Cy5) of ≥ 1.0 and ≤ −1.0 within a 99% confidence
interval (CI) were considered differentially expressed.
Microarray data are available on the Gene Expression
Omnibus (GEO) database (GSE57955). Integrative analysis
was performed using the correlation function of the
Hmisc package (http://cran.r-project.org).
Quantitative bisulfite pyrosequencing and RT-qPCR
Validation using pyrosequencing included probes that
were selected based on the following criteria: P value
≤ 0.001, FDR ≤ 0.05; more than one probe representing
a gene promoter or CpG island; probe located in a CpG
island; fold change > 1.5; and gene function related to
cancer (based in Ingenuity Pathway Analysis (IPA) and
Gene Set Enrichment Analysis (GSEA) software).
Assays were performed for 20 genes in 44 PeCa, 30 SNT,
and 11 NG (Table 1). ALR1Sat and AluYB8 repetitiveregions were assessed as previously described [31]. Bisulfite
conversion of genomic DNA was performed (EZ DNA
Methylation-Gold Kit, Zymo Research Corporation,
Irvine, CA, USA). Regions flanking the altered probes
were amplified using PCR (HotStarTaq Master Mix
kit - Qiagen) and sequenced by pyrosequencing as per
the manufacturer’s instructions (PyroMark ID Q96,
Qiagen and Biotage, Uppsala, Sweden). For each gene
selected, an average of four CpG nucleotides were
investigated involving the probe represented in the
microarray (Additional file 2: Table S9). Within each
pyrosequencing assay, bisulfite conversion controls
in the dispensation order sequence were included.
To assure efficiency, 100% and 0% methylated DNA
were also included in each run (Zymo Research
Corporation).
A total of 39 PeCa, 13 SNT, and 13 NG were used for
RT-qPCR. cDNA synthesis and amplification were per-
formed as previously described [32]. Twelve of 20
genes investigated by pyrosequencing were selected for
RT-qPCR validation (Table 1). All genes presented a
fold change > 1.5 in the microarray results. In order
to normalize target gene expression, the HMBS and
GUSB genes were selected by the geNorm software
[33] from six reference candidates (ACTB, GAPDH,
GUSB, HMBS, HPRT, and RPLP0) (Additional file 2:
Table S10). Relative quantification of gene expression
was calculated according to Pfaffl [34].
Statistical analysis
Fisher’s exact test was applied to compare categor-
ical variables, while non-parametric paired (Wilcoxon
signed-rank test), unpaired (Mann–Whitney U-test),
multiple-comparison (Kruskal-Wallis with Post Hoc
Dunn’s test), and correlation (Spearman) tests were
used to compare continual data (RT-qPCR and pyrose-
quencing results) with clinical-pathological variables. In
order to adjust the P value for the number of hypoth-
eses tested, Bonferroni’s correction was applied. The
Kaplan-Meier method alongside the log-rank test was
used to compare overall cancer-specific and disease-free
survival between groups. Multivariate analysis was
performed with Cox proportional hazards, including
variables with P value <0.2 in the univariate analysis.
Significance was considered as two-tailed P value <0.05.
Data from the paired and unpaired tests were analyzed
using SPSS 17.0 (SPSS Inc; Chicago, IL, USA) and
Graphpad Prism 5.0 (GraphPad Software Inc., La Jolla,
CA, USA).
The hierarchical clustering analysis (HCL) method was
used for the clustering analysis. Each cluster obtained
was associated to the clinical data, with the comparison
between clusters being performed by non-parametric
chi-square (χ2) test.
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The biological function, canonical pathways, and upstream
regulators were investigated by an in silico molecular
interaction analysis using Ingenuity Pathways Analysis
(IPA, Ingenuity® Systems) software. Biological function
and canonical pathways were confirmed via Gene Set
Enrichment Analysis (GSEA) and KEGG Orthology Based
Annotation System (KOBAS), which use the BioCyc,
KEGG Pathway, Pathway Interaction Database, Reactome,
and Panther databases. An FDR < 0.05 and corrected
P value < 0.05 were considered for GSEA and KOBAS,
respectively.Additional files
Additional file 1: Figure S1 to S4. Figure S1. Flow chart of
experimental design. Eighty-seven samples were obtained: 44 PeCa, 30
SNT, and 13 glans. Of the 44 PeCa samples, 25 were used for methylation
screening and 33 RNA samples for gene expression profiling. Several
genes were selected for further evaluation by RT-qPCR (12 genes) and
pyrosequencing (20 genes) in a microarray-dependent and independent
set of samples. PeCa: Penile carcinoma; SNT: surrounding non-malignant
tissue; NG: normal glans. Figure S2. Dot plot of pyrosequencing analysis.
Graphics show the methylation levels of the ALR1Sat and AluYB8 regions
and 20 probes (representing 20 genes) in NG, SNT, and PeCa samples
(unpaired analysis). NG: normal glans tissue; SNT: surrounding non-malignant
tissue; PeCa: penile carcinoma; ns: not significant; *: P value ≤0.05.
Figure S3. Relative expression of 12 selected genes by RT-qPCR. NG: normal
glans tissues; SNT: surrounding non-malignant tissue; PeCa: penile
carcinoma; ns: not significant; *: P value ≤ 0.05. Mann Whitney test was
applied for SOX3 (P value ≤0.05) to compare SNT vs PeCa. For all other
genes, the Kruskal-Wallis test was applied. Figure S4. Methylation heat
maps according to tumor grade (1, 2, and 3) and Kaplan-Meier curves in
relation to NKX2-3 and BDNF methylation levels. Comparison between
tumor grades revealed significant differences in methylation levels. A)
Difference between histological tumor grades 1, 2, and 3. B) Grade 1
tumors revealed a distinct methylation profile when compared to grade
3 tumors. C and D) Low methylation levels of the NKX2-3 and BDNF
genes were associated with a shorter disease-free survival. Survival
analysis was performed with methylation categorized for each gene as:
high level, one standard deviation above the mean of the non-tumor
group; or low level, one standard deviation below the mean of the
non-tumor group.
Additional file 2: Table S1 to S10. Table S1. List of hypermethylated
probes. ID for NCBI access, probe ID of the altered probe, FDR, fold
change, and chromosome position. Table S2. Top 100 differentially
expressed genes (under- and overexpressed) in PeCa. Table S3.
Integrative analysis for transcriptome data and methylation profile,
according to HPV status. Table S3. Integrative analysis for transcriptome
data and methylation profile, according to HPV status. Table S4. Top
ranked pathways obtained from the 122 differentially methylated
probes for the grade 3 tumors. KOBAS and GSEA software were used
for the enrichment analysis. Table S5. Comparison between gene
methylation pattern and transcript levels with clinical and pathologic
parameters. Table S6. Top ranked functions and canonical pathways
as identified by in silico analysis. Under- and overexpressed and
hypermethylated genes were used as input in the IPA, KOBAS, and
GSEA software. Table S7. Genes provided from the upstream regulator
analysis (Ingenuity Pathways Analysis software (IPA)). Genes in the first
column were altered (under- or overexpressed) in PeCa and are known
to regulate several genes identified as differentially expressed in the
transcriptome analysis. Table S8. Clinical and pathological characteristics of
the penile carcinomas patients. Table S9. Primer sequences and probe
properties for those evaluated by pyrosequencing. Table S10. Primer
sequences and transcript properties for those evaluated by RT-qPCR.Abbreviations
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